RQA membership is a great way to connect with your QA colleagues.
More information
Join the community - networking, discussion and more. Open to all.
More information
Could you write an interesting article for the RQA community?
More information1st July 2026
Summary: At its meeting from 8th to 11th June 2026, the PRAC reviewed the safety of medicines authorised in the European Union and adopted recommendations to help ensure their safe use. The committee considered new pharmacovigilance data, assessed potential safety signals, and made recommendations on risk minimisation measures, product information updates and ongoing safety monitoring where appropriate. The meeting highlights provide an overview of the committee's latest work to protect public health by continuously monitoring the benefits and risks of medicines throughout their lifecycle.